Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (21-30 of 179) with videos related to

Pageof 18
Sort By:
Future Oncology (London, England)|May 28, 2021
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancerNaomi Rm Schwartz, Kendra DeBusk, Andres Forero-Torres, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 22, 2005
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion proteinSui Shen, Ruby Meredith, Jun Duan, et al.
The Oncologist|August 3, 2012
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studiesAndres Forero-Torres, Michelle Fanale, Ranjana Advani, et al.
Oncotargets and Therapy|May 12, 2018
A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumorsTodd M Bauer, Manish R Patel, Andres Forero-Torres, et al.
Future Oncology (London, England)|August 31, 2021
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysisKendra DeBusk, Shaun Abeysinghe, Adrian Vickers, et al.
Clinical Breast Cancer|August 12, 2011
Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapyJennifer De Los Santos, Wanda Bernreuter, Kimberly Keene, et al.
Seminars in Oncology|August 31, 2015
Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Gloria J Morris, Shaheenah Dawood, Javier Cortes, et al.
Molecular Cancer Therapeutics|April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor ModelsAnita Kulukian, Patrice Lee, Janelle Taylor, et al.
Medicine and Science in Sports and Exercise|May 25, 2017
Physical Activity and Sleep Quality in Breast Cancer Survivors: A Randomized TrialLaura Q Rogers, Kerry S Courneya, Robert A Oster, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanomaAndres Forero, Jatin Shah, Ronda Carlisle, et al.
Pageof 18

Showing results (21-30 of 179) with videos related to

Sort By:
Pageof 18
Future Oncology (London, England)|May 28, 2021
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancerNaomi Rm Schwartz, Kendra DeBusk, Andres Forero-Torres, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 22, 2005
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion proteinSui Shen, Ruby Meredith, Jun Duan, et al.
The Oncologist|August 3, 2012
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studiesAndres Forero-Torres, Michelle Fanale, Ranjana Advani, et al.
Oncotargets and Therapy|May 12, 2018
A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumorsTodd M Bauer, Manish R Patel, Andres Forero-Torres, et al.
Future Oncology (London, England)|August 31, 2021
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysisKendra DeBusk, Shaun Abeysinghe, Adrian Vickers, et al.
Clinical Breast Cancer|August 12, 2011
Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapyJennifer De Los Santos, Wanda Bernreuter, Kimberly Keene, et al.
Seminars in Oncology|August 31, 2015
Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Gloria J Morris, Shaheenah Dawood, Javier Cortes, et al.
Molecular Cancer Therapeutics|April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor ModelsAnita Kulukian, Patrice Lee, Janelle Taylor, et al.
Medicine and Science in Sports and Exercise|May 25, 2017
Physical Activity and Sleep Quality in Breast Cancer Survivors: A Randomized TrialLaura Q Rogers, Kerry S Courneya, Robert A Oster, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanomaAndres Forero, Jatin Shah, Ronda Carlisle, et al.
Pageof 18